Study of IBI362 for heart failure with obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new medicine called IBI362 for people with heart failure and obesity. The medicine may help improve symptoms and quality of life. You must have a specific type of heart failure (HFpEF or HFmrEF) and a BMI of 28 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is 28 or higher.
- Your heart failure symptoms are moderate (NYHA class II or III).
- You have not been hospitalized for heart failure in the past month.
- Your Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score is below 80 (meaning your heart failure affects your daily life).
- You are willing to use effective birth control (if you could become pregnant) and not breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication (IBI362) to see if it can improve sleep apnea in people with obesity. You might qualify if you have moderate to severe sleep apnea and a BMI of 28 or higher, whether or not you currently use a CPAP machine.
This study tests whether weight loss treatments can improve muscle and blood vessel function in people with a specific type of heart failure (HFpEF) who also have obesity. It may help if you have heart failure with a normal ejection fraction and a high BMI.
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
This study tests an injectable medicine (IBI362) to see if it helps lower blood pressure in people who are overweight or have obesity. You may be eligible if you have high blood pressure but are not currently taking medication for it, and you do not have diabetes or major heart problems.
This study tests a new drug called BI 3034701 to see how well people tolerate different doses. It may help with weight loss and related health issues.
This study is testing whether a new class of medications, known as GLP-1/GIP receptor agonists, can help improve symptoms and heart health in people who have heart failure with preserved ejection fraction and are overweight or obese. It is a registry that tracks participants' health over time to learn about the treatment's effects.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.